Brazil's SUS faces delays in anemia treatment access

Administrative update processes within Brazil’s Unified Health System (SUS) are delaying patient access to new treatments, specifically impacting the management of iron deficiency anemia. Although new technologies for treating adult patients were officially incorporated and the process to update Clinical Protocols and Therapeutic Guidelines (PCDTs) began three years ago, effective access to these medications in the public network has not yet materialized.

Under Ministry of Health Ordinance GM/MS No. 4.228, the availability of incorporated technologies to patients should occur within a maximum of 180 days following a decision, with a possible 90-day extension. However, the completion of this distribution flow remains under observation by industry entities. Soraya Araújo, director of the Instituto Colabore com o Futuro, noted that while treatments have been incorporated, the rapid updating of protocols is essential to ensure care reaches patients and that bureaucracy does not limit necessary treatment.

A survey by the Research Pharmaceutical Industry Association (Interfarma) highlighted broader systemic delays, noting that 67 technologies approved by the National Commission for Technology Incorporation in SUS (Conitec) are currently pending.